Related Experiment Video
Updated: Jun 4, 2025
09:42
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
2.6K
Thrombus composition and its implication in ischemic stroke assessment and revascularization treatments
Juan Marta-Enguita1, Florencio J D Machado2, Josune Orbe3
1Servicio de Neurología, Hospital Universitario Navarra, Pamplona, Navarra, Spain; Servicio de Neurología, Hospital Universitario Donostia, San Sebastián, Guipúzcoa, Spain; Laboratorio Aterotrombosis, CIMA-Universidad de Navarra, IdiSNA, Pamplona, Navarra, Spain; RICORS-ICTUS, ISCIII, Madrid, Spain.
Neurologia
|December 24, 2024
Summary
Understanding the physiopathology of ischemic stroke thrombus formation is key to developing new treatments. Analyzing clot composition and formation mechanisms offers promising therapeutic avenues.
Area of Science:
- Neurology
- Biochemistry
- Pathology
Background:
- Mechanical thrombectomy has advanced ischemic stroke treatment by enabling thrombus retrieval.
- Studying retrieved thrombi provides insights into the physiopathological processes of clot formation.
Purpose of the Study:
- To elucidate the complex mechanisms and components involved in ischemic stroke thrombus formation.
- To identify factors influencing thrombus characteristics and resistance to revascularization treatments.
Main Methods:
- Analysis of thrombus composition, including fibrin, platelets, erythrocytes, and neutrophil extracellular traps (NETs).
- Investigation of immune and coagulation pathway activation, such as platelet aggregation and von Willebrand Factor release.
- Examination of the interrelationships between thrombus components and their impact on treatment efficacy.
Main Results:
- Stroke thrombi exhibit variable proportions of fibrin/platelet-rich and erythrocyte-rich areas.
- A protective outer shell rich in fibrin, NETs, and von Willebrand Factor often surrounds thrombi.
- Thrombus composition and structure significantly affect resistance to revascularization therapies.
Conclusions:
- Understanding thrombus components and formation mechanisms is crucial for developing novel ischemic stroke therapeutics.
- Targeting these pathways holds promise for enhancing current treatments and improving patient outcomes.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
608
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
608
01:16Clot Retraction and Fibrinolysis
3.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.8K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:24Disorders of Hemostasis
699
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
699
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
467
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
467
01:09Coagulation
4.6K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
4.6K